Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Petah Tikva, Israel.
World J Biol Psychiatry. 2022 Jul;23(6):475-482. doi: 10.1080/15622975.2021.2013090.
22q11.2 deletion syndrome (22q11.2DS) is characterised by high rates of psychotic disorders and immune abnormalities. Blood-brain barrier (BBB) permeability is known to be a risk factor for schizophrenia and immune aberrations.
To evaluate the relationship between psychosis and BBB permeability in this population.
We examined two biomarkers for BBB permeability, s100β and neuron-specific enolase (NSE), in 22q11.2DS individuals with/without psychosis. The first cohort of this Israeli-Belgium study was comprised of 20 22q11.2DS adults (30.58 ± 9.42 years) afflicted with a psychotic disorder, another group of 69 non-psychotic 22q11.2DS adults (23.42 ± 8.36 years), and 58 healthy controls (26.39 ± 7.77 years). A second cohort was comprised of 18 non-psychotic 22q11.2DS Israeli children (5.83 ± 1.55 years) and 14 healthy controls (5.34 ± 1.43 years). NSE and s100β serum levels were detected in all participants.
Both factors were elevated in adults with 22q11.2DS compared to healthy controls, specifically in the non-psychotic sub-group. In contrast, there were no significant differences in their levels between the two groups of the paediatric cohort.
Increased BBB permeability seems to be a trait of 22q11.2DS that evolves sometime in early adulthood. Our findings are in line with previous reports on non-syndromic schizophrenia, and suggest potential novel neural pathways to psychosis in 22q11.2DS.
22q11.2 缺失综合征(22q11.2DS)的特征是精神疾病和免疫异常的发生率较高。血脑屏障(BBB)通透性已知是精神分裂症和免疫异常的危险因素。
在该人群中评估精神病与 BBB 通透性之间的关系。
我们检查了 22q11.2DS 个体中与精神病相关的两种 BBB 通透性生物标志物,即 S100β和神经元特异性烯醇化酶(NSE)。这项以色列-比利时研究的第一个队列包括 20 名患有精神病的 22q11.2DS 成人(30.58±9.42 岁),另一组 69 名非精神病性 22q11.2DS 成人(23.42±8.36 岁)和 58 名健康对照者(26.39±7.77 岁)。第二个队列包括 18 名非精神病性 22q11.2DS 以色列儿童(5.83±1.55 岁)和 14 名健康对照者(5.34±1.43 岁)。所有参与者均检测了 NSE 和 S100β 血清水平。
与健康对照组相比,22q11.2DS 成人的这两个因素均升高,特别是在非精神病组中。相比之下,在儿科队列的两组之间,其水平没有显著差异。
BBB 通透性增加似乎是 22q11.2DS 的特征,在成年早期某个时候发展而来。我们的研究结果与先前关于非综合征性精神分裂症的报告一致,这表明在 22q11.2DS 中存在潜在的新的精神疾病神经通路。